MNG529
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.312
- CHOLESTEROL_HOMEOSTASIS+0.287
- ESTROGEN_RESPONSE_EARLY+0.284
- ANDROGEN_RESPONSE+0.276
- KRAS_SIGNALING_DN+0.270
- MYC_TARGETS_V1+0.264
- ESTROGEN_RESPONSE_LATE+0.236
- XENOBIOTIC_METABOLISM+0.234
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.223
- BILE_ACID_METABOLISM+0.222
Top 10 suppressed
- E2F_TARGETS-0.447
- G2M_CHECKPOINT-0.407
- ANGIOGENESIS-0.297
- INTERFERON_ALPHA_RESPONSE-0.297
- WNT_BETA_CATENIN_SIGNALING-0.295
- MITOTIC_SPINDLE-0.277
- INTERFERON_GAMMA_RESPONSE-0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.216
- IL6_JAK_STAT3_SIGNALING-0.211
- KRAS_SIGNALING_UP-0.185
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518204 | — | F | 0.754 |
| 2 | MNG384 | — | — | 0.720 |
| 3 | SRR8943024 | — | — | 0.713 |
| 4 | SRR8518189 | — | F | 0.691 |
| 5 | 8f673a13-7f81-4685-a415-645ff6b5e2fb | — | — | 0.688 |
| 6 | SRR1471817 | GTEX | — | 0.688 |
| 7 | 5085CE66-190D-478B-9AB6-55AE71C41CCF | — | — | 0.687 |
| 8 | SRR1313112 | — | B | 0.685 |
| 9 | 60703_S134 | — | cohortA1 | 0.683 |
| 10 | SRR8518241 | — | F | 0.682 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.312 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.287 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.284 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.276 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.264 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.236 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.234 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.223 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.222 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.203 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.201 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.199 | Temsirolimus | — uncovered |
| PEROXISOME | 0.179 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.153 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.153 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.137 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.131 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.128 | Inavolisib | — uncovered |
| MYOGENESIS | 0.101 | Inavolisib | — uncovered |